Loading...
Carisma Therapeutics Q1 2025 Earnings Report
Carisma Therapeutics reported a decrease in net loss and total operating expenses, while collaboration revenues saw a slight increase in Q1 2025.
Key Takeaways
Carisma Therapeutics Inc. reported a net loss of $9.266 million for Q1 2025, an improvement from a net loss of $18.978 million in Q1 2024. Collaboration revenues increased slightly to $3.729 million from $3.397 million in the prior year. The company's total operating expenses significantly decreased to $13.063 million from $22.907 million, primarily due to reductions in research and development and general and administrative expenses.
Net loss decreased to $9.266 million in Q1 2025 from $18.978 million in Q1 2024.
Collaboration revenues increased to $3.729 million in Q1 2025 from $3.397 million in Q1 2024.
Total operating expenses significantly decreased to $13.063 million in Q1 2025 from $22.907 million in Q1 2024.
Cash and cash equivalents were $7.740 million as of March 31, 2025, down from $17.909 million at December 31, 2024.
Revenue by Segment
Forward Guidance
Carisma Therapeutics Inc. anticipates continued significant expenses and operating losses as it explores strategic alternatives and winds down operations. The company does not expect current cash and cash equivalents to sustain operations for more than one year from the report date, indicating substantial doubt about its ability to continue as a going concern.
Positive Outlook
- Potential for future milestone and royalty payments from Moderna collaboration.
- Exploration of strategic alternatives to maximize value, including asset sales, licensing, or partnerships.
- Ability to pursue in vivo CAR-M programs outside of the 12 nominated oncology targets and product polypeptides.
- Potential to resume research and development activities if significant additional funding or a strategic transaction is secured.
- Focus on maximizing value of assets like CT-2401, CT-1119, and the macrophage and monocyte engineering platform.
Challenges Ahead
- Substantial doubt about the company's ability to continue as a going concern due to insufficient cash and cash equivalents.
- No current intention to resume research and development activities without significant additional funding or a strategic transaction.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...